Evidence map›Paper›PMID 38913826›Full record

ArticleFuture oncology (London, England)2024

Practice efficiency and total cost of care with bispecifics and CAR-T in relapsed/refractory diffuse large B-cell lymphoma: an institutional perspective.

Matthew Lei, Qianyi Li, Ken O'Day, Kellie Meyer, Anthony Wang, Monika P Jun

Erratum issuedAbstract read
In one paragraph

Article in Future oncology (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Matthew LeiPharmacy Department, Massachusetts General Hospital, Boston, MA  02114, USA.ORCID 0000-0001-5348-6065
Qianyi LiMarket Access & Healthcare Consulting, Cencora, Conshohocken, PA 19428, USA.
Ken O'DayMarket Access & Healthcare Consulting, Cencora, Conshohocken, PA 19428, USA.
Kellie MeyerMarket Access & Healthcare Consulting, Cencora, Conshohocken, PA 19428, USA.
Anthony WangHealth Economics and Outcomes Research, AbbVie Inc., North Chicago, IL  60064, USA.
Monika P JunCenter for Outcomes Research, Real-world Evidence and Epidemiology, Genmab US, Inc., Plainsboro, NJ  08536, USA.

Funding

AbbVieGenmab
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antibodies, BispecificCost-Benefit AnalysisImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseBiological ProductsHealth Care CostsHumansNeoplasm Recurrence, LocalReceptors, Chimeric AntigenAntibodies, Bispecificaxicabtagene ciloleucelBiological ProductsReceptors, Chimeric Antigenbispecific antibodiesCAR T-cell therapychair timecost of carediffuse large B-cell lymphomaepcoritamabglofitamabinstitutional modelpractice efficiencystaff time

Identifiers

PMID38913826
PMCPMC11508956

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.